1 / 4

Somatostatin Receptor Type 4 (SSTR4) H1 2017 Therapeutics Review Featuring Drug Profiles Analysis

According to the recently published report 'Somatostatin Receptor Type 4 (SSTR4) - Pipeline Review, H1 2017'; Somatostatin Receptor Type 4 (SSTR4) pipeline Target constitutes close to 6 molecules.

hexareports1
Download Presentation

Somatostatin Receptor Type 4 (SSTR4) H1 2017 Therapeutics Review Featuring Drug Profiles Analysis

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Somatostatin Receptor Type 4 (SSTR4) H1 2017 Therapeutics Review Featuring Drug Profiles Analysis “Somatostatin Receptor Type 4 (SSTR4) H1 2017, provides in depth analysis ontherapeutics under development by companies & drug profiles study based on mechanism of action (MoA), route of administration (RoA) and molecule type” According to the recently published report 'Somatostatin Receptor Type 4 (SSTR4) - Pipeline Review, H1 2017'; Somatostatin Receptor Type 4 (SSTR4) pipeline Target constitutes close to 6 molecules. Out of which approximately 5 molecules are developed by companies and remaining by the universities/institutes. Somatostatin Receptor Type 4 (SSTR4) - Somatostatin receptor type 4 is a protein encoded by the SSTR4 gene. The activity of receptor is mediated by G proteins which inhibits adenylyl cyclase. It mediates antiproliferative action of somatostatin in tumor cells. It is functionally coupled to inhibition of adenylate cyclase and activation of both arachidonate release and mitogen-activated protein (MAP) kinase cascade. The report 'Somatostatin Receptor Type 4 (SSTR4) - Pipeline Review, H1 2017' outlays comprehensive information on the Somatostatin Receptor Type 4 (SSTR4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities. Browse Detail Market Report With TOC @ http://www.hexareports.com/report/somatostatin-receptor-type-4-sstr4-pipeline-review-h1-2017 Follow Us:

  2. It also reviews key players involved in Somatostatin Receptor Type 4 (SSTR4) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Preclinical and Discovery stages are 1, 1 and 3 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Central Nervous System, Hormonal Disorders, Metabolic Disorders and Oncology which include indications Chronic Pain, Acromegaly, Neuropathic Pain, Alzheimer's Disease, Cognitive Disorders, Dementia, Diabetic Retinopathy, Gastrointestinal Tumor, Neuroendocrine Tumors, Pancreatic Tumor and Pituitary ACTH Hypersecretion (Cushing Disease). Request A Sample copy of This Report @ http://www.hexareports.com/report/somatostatin- receptor-type-4-sstr4-pipeline-review-h1-2017/request-sample Scope - The report provides a snapshot of the global therapeutic landscape for Somatostatin Receptor Type 4 (SSTR4) - The report reviews Somatostatin Receptor Type 4 (SSTR4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre- registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Somatostatin Receptor Type 4 (SSTR4) targeted therapeutics and enlists all their major and minor projects - The report assesses Somatostatin Receptor Type 4 (SSTR4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Somatostatin Receptor Type 4 (SSTR4) targeted therapeutics Reasons To Buy 1.Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies Follow Us:

  3. 2.Identify emerging players with potentially strong product portfolio and create effective counter- strategies to gain competitive advantage 3.Identify and understand the targeted therapy areas and indications for Somatostatin Receptor Type 4 (SSTR4) 4.Identify the use of drugs for target identification and drug repurposing 5.Identify potential new clients or partners in the target demographic 6.Develop strategic initiatives by understanding the focus areas of leading companies 7.Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics 8.Devise corrective measures for pipeline projects by understanding Somatostatin Receptor Type 4 (SSTR4) development landscape 9.Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Browse More Pharmaceuticals & Healthcare Related Market Research Reports: •Idiopathic Pulmonary Fibrosis - Pipeline Review, H1 2017 http://www.hexareports.com/report/idiopathic-pulmonary-fibrosis-pipeline-review-h1-2017 •Myocardial Ischemia - Pipeline Review, H1 2017: http://www.hexareports.com/report/myocardial-ischemia-pipeline-review-h1-2017 •Malignant Pleural Effusion - Pipeline Review, H1 2017: http://www.hexareports.com/report/malignant-pleural-effusion-pipeline-review-h1-2017 Follow Us:

  4. About Us: Hexa Reports is a market research and consulting organization, offering industry reports, custom research and consulting services to a host of key industries across the globe. We offer comprehensive business intelligence in the form of industry reports which help our clients obtain clarity about their business environment and enable them to undertake strategic growth initiatives. Contact Information: Ryan Shaw Felton Office Plaza, 6265 Highway 9, Felton, California, 95018, United States Phone Number 1-800-489-3075 Email Us: sales@hexareports.com Our Website: http://www.hexareports.com/ Follow Us:

More Related